Grant name: Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders
Funding organization: National Institutes of Health (NIH)
Total funding amount: $27,000,000 for FY 2026
Duration: Maximum project period of 3 years
Primary objective: Support early-stage testing of pharmacologic interventions and neuromodulatory devices for mental disorders
Key stakeholders: National Institute of Mental Health (NIMH), applicants from various eligible organizations
Funding source: Federal government
Funding type: Grant
Significance: Addresses the need for innovative mental health treatments
Grant frequency: Recurring
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations (including Small Businesses)
Local, State, County, City Governments
Indian/Native American Tribal Governments (both recognized and non-recognized)
Federal Agencies
Foreign Organizations
Organizations must complete registrations with SAM, eRA Commons, and Grants.gov prior to application submission.
Principal Investigators must have an eRA Commons account.
Testing of pharmacologic interventions with novel mechanisms of action
Neuromodulatory device-based interventions
Early intervention studies for mental disorders
Individuals with mental illnesses across pediatric, adult, and geriatric populations
Experience in conducting clinical trials, particularly in pharmacologic or device-based interventions
Ability to demonstrate target engagement and measure clinical outcomes
Application budgets are not limited but must reflect actual project needs.
Open Date: January 14, 2025
Application Due Dates: Various dates through 2027
Earliest Start Date: February 14, 2025
Must adhere to FDA regulations for investigational drugs/devices.
Compliance with NIH policies on human subjects and data sharing.
Applications must follow the Research Instructions in the How to Apply - Application Guide.
Preliminary data demonstrating target engagement is required.
Encourages innovative approaches and high-risk projects.
Applications must demonstrate a clear rationale for the proposed interventions.